News

In honor of World Sleep Day, held March 17, 2023, get caught up on some of the latest news in sleep disorders as the NeurologyLive® team shares some of our data updates.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 17, 2023.

The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]

Here's the latest multidisciplinary MS research published online first in the International Journal of MS Care.

The neurologist at Mayo Clinic, in Jacksonville, Florida, spoke about inebilizumab as a treatment for NMOSD and other autoimmune diseases, such as encephalitis, in the ExTINGUISH trial. [WATCH TIME: 3 minutes]

Ahead of the 2023 MDA Clinical and Scientific Conference, Anne Connolly, MD, provided perspective on conversations surrounding holistic approaches to neuromuscular diseases.

Marcus Carstensen, PhD candidate, CTO and co-founder of OptoCeutics in Copenhagen, Denmark, talked about the mechanisms of using noninvasive light technologies for Alzheimer disease treatment.

In honor of Brain Awareness Week, held March 13, 2023, to March 19, 2023, get caught up on some of the latest news in neurology as the NeurologyLive® team shares some of our data updates.

The vice president of Health Economics and Outcomes Research at Acadia Pharmaceuticals provided perspective on the mechanistic advantages of pimavanserin over atypical antipsychotics to treat Parkinson disease psychosis. [WATCH TIME: 2 minutes]

The director of the Comprehensive Epilepsy Center at NYU Langone discussed the importance of healthy eating habits and whether all individuals with epilepsy should consider dieting early in their life. [WATCH TIME: 4 minutes]

At the 2023 ACTRIMS forum, Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, talked about investigating the relationship between viral infections and multiple sclerosis using MRIs.

A comparison of narcolepsy cases from the Russian Narcolepsy Network did not differ from data in the European Narcolepsy Network.

In honor of National Sleep Awareness Week, a group of experts in the care of patients with sleep disorders—Wendy Troxel, PhD; Garth Whiteside; Milena Pavlova, MD; Ronald Gavidia, MD, MS; Renee Shellhaas, MD, MS, FAES—shared their perspectives on hot topics of treatment and management in sleep medicine.

In a recent interview, the associate professor at Harvard Medical School spoke about patient-centered research in the advancing treatment for patients with NMOSD. [WATCH TIME: 5 minutes]

Michael Dwyer, PhD, director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center, provided insight on how artificial intelligence techniques may be used to monitor disease progression in multiple sclerosis.

The director of functional neurosurgery at Baptist Health Miami Neuroscience Institute provided perspective on the growth of high intensity focused ultrasound and the lessons learned when treating essential tremor.

Jeffery Neul, MD, PhD, director of the Vanderbilt Kennedy Center, and professor of pediatrics at Vanderbilt University Medical Center, shared his reactions and thoughts to the approval of trofinetide.

In honor of Brain Awareness Week, a group of experts in the care of patients with neurological conditions—Ronald C. Petersen, MD, PhD; Brian Grosberg, MD, FAHS; James Beck, PhD; Michael Levy, MD, PhD; Stanley H. Appel, MD —shared their perspectives on hot topics of treatment and management in neurology.

Published findings showed that narcolepsy has a significant impact on social relationships in adolescents, thus suggesting that structured routine for assessing social health is a vital first step for treatment.

At the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]

Plasma P-tau217 was associated with cognitive decline across several cognitive tests in 2 different cohorts and with conversion to AD dementia in the large-scale, longitudinal BioFINDER-1 cohort.

Originally approved under the accelerated approval pathway, a final decision on a traditional approval for lecanemab is expected to come in early July.

Findings showed that global cognition declines in the prediagnostic period in men but not women with incident Parkinson disease, further indicating cognitive heterogeneity in the prodromal period by sex.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Jeffrey L. Neul, MD, PhD. [LISTEN TIME: 12 minutes]

Among countries with non-zero mechanical thrombectomy access, there was a 460-fold difference in availability of this care between the country with the highest and lowest access rate reported.

At the 2023 ACTRIMS Forum, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary talked about the main findings he observed with B cell therapies in patients with MS. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Omar Al-Louzi, MD, director of the Visual Outcomes Laboratory at Cedars Sinai, provided his clinical perspective on role of imaging and viral infections in patients with MS at the 2023 ACTRIMS forum.